Morgan Stanley
CBAY

Morgan Stanley’s Cymabay Therapeutics CBAY Stock Holding History

Morgan Stanley’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,913,890
Closed -$45.2M – 8032
2023
Q4 		$45.2M Buy
1,913,890
+1,406,419
+277% +$25M ﹤0.01% 2564
2023
Q3 		$7.57M Sell
507,471
-316,228
-38% -$4.19M ﹤0.01% 3374
2023
Q2 		$9.02M Sell
823,699
-168,682
-17% -$1.57M ﹤0.01% 3258
2023
Q1 		$8.65M Buy
992,381
+719,302
+263% +$5.76M ﹤0.01% 3269
2022
Q4 		$1.71M Buy
273,079
+55,377
+25% +$210K ﹤0.01% 4553
2022
Q3 		$763K Sell
217,702
-245,749
-53% -$883K ﹤0.01% 5043
2022
Q2 		$1.37M Buy
463,451
+338,932
+272% +$810K ﹤0.01% 4809
2022
Q1 		$388K Buy
124,519
+13,720
+12% +$43.2K ﹤0.01% 5558
2021
Q4 		$374K Sell
110,799
-69,069
-38% -$262K ﹤0.01% 5720
2021
Q3 		$656K Sell
179,868
-327,215
-65% -$1.29M ﹤0.01% 5333
2021
Q2 		$2.21M Buy
507,083
+390,907
+336% +$1.73M ﹤0.01% 4549
2021
Q1 		$527K Buy
116,176
+40,484
+53% +$218K ﹤0.01% 5124
2020
Q4 		$435K Buy
75,692
+12,635
+20% +$95.6K ﹤0.01% 5167
2020
Q3 		$456K Sell
63,057
-218,030
-78% -$1.17M ﹤0.01% 4697
2020
Q2 		$981K Buy
281,087
+124,573
+80% +$359K ﹤0.01% 4185
2020
Q1 		$232K Sell
156,514
-2,274,946
-94% -$3.82M ﹤0.01% 4800
2019
Q4 		$4.76M Buy
2,431,460
+2,007,849
+474% +$7.54M ﹤0.01% 3255
2019
Q3 		$2.17M Buy
423,611
+417,179
+6,486% +$2.53M ﹤0.01% 3705
2019
Q2 		$45K Sell
6,432
-26,046
-80% -$295K ﹤0.01% 5649
2019
Q1 		$432K Sell
32,478
-277,646
-90% -$2.95M ﹤0.01% 4628
2018
Q4 		$2.44M Buy
310,124
+191,424
+161% +$1.82M ﹤0.01% 3598
2018
Q3 		$1.31M Sell
118,700
-32,350
-21% -$402K ﹤0.01% 4321
2018
Q2 		$2.03M Buy
151,050
+106,502
+239% +$1.33M ﹤0.01% 4069
2018
Q1 		$579K Sell
44,548
-9,724
-18% -$121K ﹤0.01% 4919
2017
Q4 		$499K Sell
54,272
-2,752
-5% -$23.5K ﹤0.01% 4983
2017
Q3 		$460K Buy
57,024
+35,946
+171% +$243K ﹤0.01% 4928
2017
Q2 		$121K Buy
21,078
+4,714
+29% +$20.1K ﹤0.01% 5564
2017
Q1 		$71K Buy
16,364
+14,189
+652% +$40.7K ﹤0.01% 5723
2016
Q4 		$4K Buy
2,175
+775
+55% +$1.37K ﹤0.01% 6312
2016
Q3 		$3K Buy
1,400
+1,100
+367% +$2.19K ﹤0.01% 6332
2016
Q2 		$1K Buy
300
+150
+100% +$311 ﹤0.01% 6456
2016
Q1 		$0 Buy
+150
New +$186 ﹤0.01% 6761
2015
Q4 		– Sell
-2,568
Closed -$5K – 6837
2015
Q3 		$5K Hold
2,568
– – ﹤0.01% 6385
2015
Q2 		$7K Sell
2,568
-85,603
-97% -$352K ﹤0.01% 6381
2015
Q1 		$610K Buy
88,171
+68,912
+358% +$662K ﹤0.01% 4520
2014
Q4 		$189K Buy
19,259
+19,234
+76,936% +$155K ﹤0.01% 5268
2014
Q3 		$0 Buy
+25
New +$154 ﹤0.01% 6686

Other funds holding CBAY

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Morgan Stanley's CBAY Position: Q1 2024 in Review

Morgan Stanley sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 1,913,890 shares — an estimated $45.2M sold.

Morgan Stanley first reported a position in CBAY in Q3 2014 and held it in 37 quarters. The position peaked at $45.2M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

  • Morgan Stanley reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Morgan Stanley sold 1,913,890 Cymabay Therapeutics shares in Q1 2024, an estimated $45.2M.
  • Morgan Stanley first reported a position in Cymabay Therapeutics in Q3 2014 and held it in 37 quarters.
  • Morgan Stanley's Cymabay Therapeutics position peaked at $45.2M in Q4 2023.
  • 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Morgan Stanley's 13F filing for Q1 2024, filed 15 May 2024.